KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBT Margin (2016 - 2025)

Historic EBT Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 5.31%.

  • Pacira BioSciences' EBT Margin rose 876800.0% to 5.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.84%, marking a year-over-year increase of 137400.0%. This contributed to the annual value of 9.0% for FY2024, which is 181400.0% down from last year.
  • As of Q3 2025, Pacira BioSciences' EBT Margin stood at 5.31%, which was up 876800.0% from 1.06% recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' EBT Margin ranged from a high of 22.34% in Q2 2023 and a low of 82.37% during Q3 2024
  • Its 5-year average for EBT Margin is 3.0%, with a median of 8.16% in 2024.
  • As far as peak fluctuations go, Pacira BioSciences' EBT Margin crashed by -925000bps in 2024, and later skyrocketed by 876800bps in 2025.
  • Pacira BioSciences' EBT Margin (Quarter) stood at 3.89% in 2021, then crashed by -170bps to 10.51% in 2022, then surged by 277bps to 18.6% in 2023, then fell by -27bps to 13.63% in 2024, then tumbled by -61bps to 5.31% in 2025.
  • Its last three reported values are 5.31% in Q3 2025, 1.06% for Q2 2025, and 5.15% during Q1 2025.